Epiliquid

We are a biotechnology startup aiming to make early cancer detection accessible to all individuals. We want to improve the population's quality of life by developing a liquid biopsy technology platform sensitive, affordable, and accessible. Team Innovation We have developed a biomarker detection platform in blood using simple equipment. By focusing on precision and mass accessibility, we seek to ensure the benefits of early cancer detection reach more people, paving the way for a healthier population, minimizing the global economic impact of cancer. To achieve our purpose, we gathered a multidisciplinary team of highly qualified professionals who combine years of scientific research, extensive experience in life sciences and biotechnology, and thousands of lines of analyzed bioinformatic data. This convergence enhances our ability to offer cutting-edge solutions and leverage diverse experiences, ensuring that we remain at the forefront of the liquid biopsy research and markets, projected to reach USD 18 billion by 2032. Technology Vanguard We harness the power of big data and artificial intelligence through our bioinformatic platform. This enables us to identify sensitive and specific biomarkers for different types of cancer, considering their clinical utility. Our patented technology allows for minimally invasive early cancer detection, setting a new standard in contrast to existing technologies. Additionally, we employ various techniques, methods, and technologies to remain at the forefront of Liquid Biopsy for detecting and quantifying sensitive and specific biomarkers. >>> Join our mission to detect cancer early and impact public health globally.